Infinity Pharmaceuticals

we are relentlessly pursuing excellence – daring to believe that a cure can be a reality. infinity pharmaceuticals, inc., is a clinical-stage biotechnology company developing eganelisib (ipi-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. mario-275 is a randomized, controlled combination study of eganelisib combined with opdivo® in i/o naïve urothelial cancer. mario-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with tecentriq® and abraxane® in front-line tnbc and in combination with tecentriq and avastin® in front-line rcc. in collaboration with arcus biosciences, infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (ab928, a dual adenosine receptor antagonist) plus doxil® in advanced tnbc patients. in 2019, infinity completed enrollment in mario-1, a phase 1/1b study evaluating eganelisib as a monotherapy and in combination with opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. with these studies, infinity is evaluating eganelisib in the anti-pd-1 refractory, i/o-naïve, and front-line settings. for more information on infinity, please refer to infinity\'s website at www.infi.com.

查找电子邮件地址

使用 tomba.io 快速尝试一下。 tomba.io.

从列表中查找电子邮件地址从 Google 开始